A biotechnology company focused on developing therapeutics for systemic amyloidosis.

Attralus

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

venBio Partners

Redmile Group

Samsara BioCapital

Sarissa Capital Management

Janus Henderson Investors

Logos Capital

Surveyor Capital

Vivo Capital

Attralus 

We’re #hiring a new CMC Project Manager. Apply today or share this post with your network.

We’re #hiring for a Senior Director, Clinical Operations. Apply today or share this post with your network.

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (#ISA2024)

✳ Read the press release at https://lnkd.in/ebkEEYcV.
 
✳ In total, 16 presentations covering AT-01, AT-02, AT-05 and AT-06 were presented, including three oral presentations, highlighting our pipeline of investigational systemic amyloidosis therapies and diagnostics. 

✳ AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients with systemic amyloidosis.

✳ AT-01, the first pan-amyloid diagnostic imaging agent, demonstrated high levels of sensitivity and specificity for detection of cardiac amyloid.

✳ ISA took place in Rochester, MN on 26-30 May 2024. For additional information, visit the ISA 2024 website (https://lnkd.in/eM3S93K5).
 
✳ View conference posters and presentations on our website (https://lnkd.in/eDVZcDxq).

#amyloidosis #rarediseases
 
Liked this post? Want to see more?
 🔔 Sign up for alerts to be notified of our newest posts
 #️⃣ Follow - #Attralus
 🌏 https://www.attralus.com

Attralus continues our strong commitment to patients with systemic amyloidosis at the 2024 International Symposium on #Amyloidosis (ISA). We look forward to seeing you there.
 
✳ 16 presentations covering AT-01, AT-02, AT-05 and AT-06 will be presented, including three oral presentations, highlighting our pipeline of investigational systemic amyloidosis therapies and diagnostics. 

✳ The International Symposium on Amyloidosis (ISA) takes place this year in Rochester, MN from May 26–30, 2024.
 
✳ View posters and presentations on our website following the meeting at https://lnkd.in/eDVZcDxq. 

#amyloidosis #rarediseases #diagnostic
 
Liked this post? Want to see more?
 🔔 Sign up for alerts to be notified of our newest posts
 #️⃣ Follow - #Attralus
 🌏 https://www.attralus.com

We are excited to announce the closing of our $56 million financing. Read the press release at https://lnkd.in/ecAsrj7C

#amyloidosis
__________________________________________________

Liked this post? Want to see more?
🔔 Sign up for alerts to be notified of our newest posts
#️⃣ Follow - #Attralus
🌏 https://www.attralus.com

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) 

✳ The Company announced the publication of results from two Attralus-funded investigator-initiated studies of 124I-evuzamitide, the company’s investigational pan-amyloid radiotracer under development for the diagnosis and management of systemic amyloidosis

✳ Read the press release at https://lnkd.in/esQ5FpTV

✳ The manuscripts from Brigham and Women's Hospital and from the The University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging). 

✳ The two manuscripts were also accompanied by an editorial entitled “Shining a Radiant Light on Cardiac Amyloidosis with Novel 124I-Evuzamitide PET Imaging.” 

✳ All three articles can be found online at https://lnkd.in/eqVy7vRU .

#amyloidosis #rarediseases #diagnostic
__________________________________________________

Liked this post? Want to see more?
🔔 Sign up for alerts to be notified of our newest posts
#️⃣ Follow - #Attralus
🌏 https://www.attralus.com

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Jul 25, 2024 8:34 AM	eeea3fd5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Jul 25, 2024 8:34 AM	86b927f8
news basic	general	Jul 25, 2024 8:34 AM	da588b9f
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

ATTR

COM:ATTRALUS

Attralus